NCT07852494Not yet recruiting
Phenotypic and Functional Characterization of Bone Marrow Macrophages in Chronic Myelomonocytic Leukemia
Phenotypic and Functional Characterization of Bone Marrow Macrophages in Chronic Myelomonocytic Leukemia (CMML): Comparative Study With Age-Matched Healthy Controls
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
MAC-AGE is a single-center study designed to characterize bone marrow macrophages in patients with chronic myelomonocytic leukemia (CMML) and to compare them with macrophages from age-matched controls undergoing elective total hip arthroplasty. Phenotypic, transcriptional and functional analyses will be performed using spectral/multiparametric flow cytometry, single-cell RNA sequencing and ex vivo functional assays. The study aims to identify CMML-associated macrophage alterations and potential therapeutic targets within the bone marrow immune microenvironment.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 25 Sept 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 1 Nov 2029
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Diseases
- Chronic myeloid leukaemia
- NCT number
- NCT07852494
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 1 Nov 2026 to the primary completion date, 1 Nov 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Age ≥ 55 years
- Confirmed diagnosis of chronic myelomonocytic leukaemia (CML) according to WHO criteria (2022 edition)
- Patient registered with or covered by a social security scheme
- Bone marrow sample can be obtained during a scheduled consultation
- Signed informed consent Exclusion criteria - Group 1
- Active infection or acute inflammatory condition
- Treatment with chemotherapy or immunosuppressants within the 4 weeks prior to the procedure
- Medical contraindication to bone marrow aspiration
- Person under guardianship, curatorship or legal protection
- Secondary CMML
- Age ≥ 55 years
- Scheduled surgery for total hip replacement
- No history of haematological malignancy or autoimmune disease
- Signed informed consent
- Patient registered with or covered by a social security scheme Exclusion criteria - Group 2
- Active or uncontrolled chronic inflammatory condition
- Autoimmune disease
- Presence of a known haematological disorder, persistent monocytosis or an unexplained haematological abnormality
- Chronic immunomodulatory or anti-inflammatory treatment
- History of immunosuppression or chronic inflammatory disease
- Persons under guardianship, curatorship or judicial protection
Age in the registry: 55 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Nice Coordinator of this site? Confirm its status | Nice | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.